WeTrials
Recruiting

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (REVERSE-LC)

What is this study?

This study tests if a medicine called baricitinib can help improve ongoing symptoms like brain fog, fatigue, and breathing issues in people with Long COVID. Researchers want to see if calming down the body's immune system can make you feel better and improve your daily quality of life.

Who can participate?

You might be able to join if you are 18 or older and have proof of a positive COVID-19 test from at least six months ago. The study is meant for people whose Long COVID symptoms started after their infection and are not caused by other pre-existing conditions.

What will happen?

During the study, you will be randomly assigned to receive either the real study medication or a placebo, which looks like the medicine but contains no active ingredients. Researchers will check your progress, symptom levels, and physical function throughout the process.

Where and when?

The study is currently recruiting participants at locations in Tucson, Arizona, as well as Los Angeles and San Francisco, California. You can visit one of these research centers to take part.

Key Points
  • 1Testing an anti-inflammatory drug called baricitinib for Long COVID
  • 2Compares the medication against a placebo to see how well it works
  • 3Open to adults with a confirmed prior COVID-19 infection and ongoing symptoms

Related video

UniteToFight 2024: lead investigator Dr. Wes Ely presents the REVERSE-LC trial (July 2024)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Long COVIDSars-CoV-2 InfectionCoronavirus InfectionsCOVID-19

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.